<DOC>
	<DOCNO>NCT00003207</DOCNO>
	<brief_summary>The rationale conduct study lie premise indeed reason limited response Kaposi 's sarcoma lesion advance malignancy chemotherapy attributable high expression P-glycoprotein , , inhibit pump , tumor kill would enhance response rate well duration response would also increase . Doxil chosen since recent study show superior combination chemotherapy ABV BV . Doxil also know active malignancy breast ovarian cancer ( 34,35 ) . PSC 833 choose since find reverse P-gp vitro vivo , non-immunosuppressive , show recent Phase 1 study well tolerate . There yet human study report Doxil pharmacokinetics combine MDR modulators . Preclinical data show pharmacokinetics Doxil , unlike free doxorubicin , minimally affected addition PSC 833 ( 36 ) . Enhanced tumor toxicity observe PSC 833 combine Doxil . Since doxorubicin , active agent Doxil , metabolize cytochrome P450 , interaction 2 agent may significant clinical implication . The purpose study assess toxicity determine maximum tolerate dose Doxil combine PSC 833 treatment AIDS-KS advanced malignancy .</brief_summary>
	<brief_title>Liposomal Doxorubicin PSC 833 Treating Patients With AIDS-Related Kaposi 's Sarcoma Other Advanced Cancers</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>INCLUSION CRITERIA Histologically document malignancy refractory standard treatment standard treatment exists , biopsy proven Kaposi 's sarcoma mucocutaneous lesion number 10 documented visceral KS lesion least 2 assessable cutaneous lesion . A life expectancy &gt; 4 month . Patients prior chemotherapy Doxil exposure eligible Age &gt; =18 Karnofsky score &gt; =70 % Hemoglobin &gt; =8 g/dl , neutrophil count &gt; =1000 cells/ul platelet count &gt; =75,000 cells/ul . Creatinine clearance .=50 ml/min creatinine &lt; =2.0mg/dl , SGOT &lt; =2X institutional normal bilirubin &lt; 1.5X institutional normal Written inform consent obtain patient . EXCLUSION CRITERIA Pregnant breast feeding patient radioactive tracer material chemotherapy use protocol . Active opportunistic infection require antibiotic treatment . Treatment radiation electron beam therapy , interferon cytotoxic therapy within precede 4 week . Clinically significant history congestive heart failure . Patients moderate severe sensory motor peripheral neuropathy . Any patient currently receive treatment follow agent discontinue specified time relative PSC 833 administration . All drug well substantiate interact cyclosporin A : Agents increase serum concentration CsA The following drug must administer 48 hour PSC 833 start , course administration , 48 hour last dose PSC 833 cycle : Calcium channel blocker : diltiazem , nicardipine , verapamil Antifungals : fluconazole ( dose &lt; 200 mg/day allow ) , itraconazole , ketoconazole Antibiotics : clarithromycin , erythromycin Others : metoclopramide , bromocriptine , danazol Agents decrease serum concentration CsA The following drug must administer 14 day PSC 833 start course administration . They may restart immediately last dose PSC 833 : Antibiotics : nafcillin , rifampin Anticonvulsants : carbamazepine , phenobarbital , phenytoin Others : octreotide , ticlopidine Hypersensitivity Doxil cyclosporin A Any patient , , judgment investigator , may able complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>AIDS-related Kaposi sarcoma</keyword>
	<keyword>recurrent Kaposi sarcoma</keyword>
</DOC>